

Miltefosine (Hexadecylphosphocholine)

Cat. No. CEI-0907

Lot. No. (See product label)

Introduction

 $\textbf{\textit{Description}} \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M and 8.1 } \mu\text{M in carcinoma cell lines A431 and } \quad \text{Miltefosine inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M inhibits PI3K/Aktactivity with ED50 of 17.2 } \mu\text{M inhibits PI3K/Aktactivity with ED50$

HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.

Phase 4.

Product Information

CAS No. 58066-85-6

Molecular C21H46NO4P

Formula

Chemical Ethanaminium, 2-[[(hexadecyloxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt

Name

Molecular 407.57

Weight

Targets PI3K

Solubility DMSO <1 mg/mL; Water 82 mg/mL; Ethanol 82 mg/mL

Storage and Shipping Information

Storage 2 years -20 centigrade Powder; 2 weeks 4 centigrade in DMSO; 6 months -80 centigrade in DMSO.

Tel: 1-631-562-8517 1-516-512-3133 **Email:** info@creative-enzymes.com

1/1